Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirasemtiv Open-Label Extension in ALS (VIGOR-ALS)
NCT02936635Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of tirasemtiv in amyotrophic lateral sclerosis (ALS), sponsored by Cytokinetics. Started Oct 2016; status: completed.
02
Drugs
tirasemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02936635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936635.